Further, for the three groups of m6A modification patterns, we also analyzed the differences in PD-L1 expression in immune cells (IC) and tumor cells (TC), patients’ response to anti-PDL1 efficacy, TMB, m6Ascore, and the important gene mutations prevalent in bladder cancer. The gene discussed is CD274; the disease is urinary bladder cancer.